Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
By A. Dispenzieri, M. Gertz, R. Kyle, M. Lacy, M. Burritt, Terry M. Therneau, P. Greipp, T. Witzig, J. Lust, S. Rajkumar and 4 more. Journal of Clinical Oncology, 2004
885 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/cd20afc7dcff44ea05479a4ead0b4a1e1e62fa21
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. (2016, background): “Prognostic stratification has been clearly described in AL patients in pivotal studies from the Mayo Clinic group, defining stage I to III of cardiac involvement based on levels of brain natriuretic peptide (BNP) and of troponin T.(61) More recently, Wechalekar et al(62) further stratified stage III”
- Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. (2013, background): “Biomarkers, particularly N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponins are useful for prognosis (19) and elevate early but nonspecifically.”
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. (2016, methodology): “On the basis of the utility of troponin and NT-proBNP to predict outcomes in AL amyloidosis (20), we developed a staging system for patients with ATTRwt, which demarcates 3 populations of patients with different OS.”
- Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012, methodology): “spectrum and severity of organ involvement, especially cardiac involvement, usually dictate early outcome, with cardiac biomarkers such as cTnT, NT-ProBNP, and serum uric acid strongly predicting for 1-year mortality.(12,26) However, the long-term outcome of patients with AL amyloidosis is likely to”